

THE TREND OF HEPATITIS B SURFACE ANTIGENEMIA AMONG TEACHING HOSPITAL PATIENTS IN KANO

* Nwokedi, E.E. ; ** Emokpae, M. A.; * Taura, A.A.;* Dutse, A. I.

*Departments Of Medical Microbiology/Parasitology,Psychiatry And Medicine. Faculty Of Medicine, Bayero University & **Department Of Chemical Pathology, Aminu Kano Teaching Hospital Kano.

Correspondence: Dr. E. E. Nwokedi. E-mail-drnwokedi@yahoo.com

ABSTRACT

The prevalence and trend of Hepatitis B Virus infection in 2966 patients attending clinics of Aminu Kano Teaching Hospital, Kano Nigeira was determined over a 3 year period 2001 to 2003. The samples was initially screened by latex agglutination techniques while the positive samples repeated by Enzyme linked Immunosorbent Assay (ELISA) technique for confirmation. A seroprevalence of 23.3% units with coefficient variation of 22.5 to 24.1% were reported during the study period. More males (24.1%) than females 21.5% patients were observed to be seropositive for HBsAg. The differences was not however statistically significant. The overall trend in HBsAg seropositivity over the study period showed 21.7% in 2001, 24.7% in 2002 and 22.4% in 2003 respectively. Despite the availability of methods by which these viruses can be detected and surveillance activities to reduce the occurrence of the infection, the virus continues to constitute threat to health of the individuals. Our findings suggest that it is necessary to reappraise the need to intensify preventive measures in order to reduce the trend of HBV infections.

Key Words: Hepatitis B, HbsAg, Blood, Serum, Samples

INTRODUCTION

Hepatitis B virus (HBV) is one of the most important hepatotropic viruses known to be transmitted sexually, percutaneously, by blood, blood products and is known to be endemic in Africa (1&2). Despite the availability of methods by which this virus can be detected and surveillance activities to reduce the occurrence of the infection, the virus continues to constitute a threat to the health of patients. Hepatitis B surface antigen (HBsAg) in the blood is the most useful marker of active HBV infection which appears in the blood exclusively as a component of the virus and as incomplete viral forms (3&4).

It has been estimated that about one third of the world's population has been infected with HBV of which over 350 millions of them are said to chronic carriers (5).

WHO estimates suggest that HBV results in two million deaths each year worldwide and 230,000 of these occurring in Africa. Even though the incidence of acute hepatitis and death as a result of it is under reported, Nigeria appears to fall within the hyperendemic region of Sub-Saharan Africa. It has been reported that upto 25% of chronic carriers of HBV develop serious liver diseases including chronic hepatitis, cirrhosis and hepatocellular carcinoma (5).

Although the prevalence of HBsAg has been reported among blood donors in this centre (6), information on its prevalence and trend of infection among patients is not available. Therefore, the aim of this study is to present the carriage rate and the trend of HBV infection among patients in Aminu Kano Teaching Hospital, (AKTH) Kano.

METHODS

Serum samples were collected from 2966 consecutive patients presenting to Aminu Kano Teaching Hospital (AKTH) for a period of three years from January 2001 to December 2003. They consist of 2095 males and 871 females. The age ranged from one year to 61 years. In 2001, 406 specimens were collected while 1282 and 1278 were collected in 2002 and 2003 respectively. The samples were screened for HBsAg by latex

agglutination technique. All positive samples were repeated using Enzyme Linked Immunosorbent Assay (ELISA) technique (pathogyme Omega Diagnostics, UK) for confirmation.

RESULTS

Out of the 2966 patients tested over the three year period, 691 (23.1%) were HBsAg positive. This gives a period prevalence of 23.3% with a 95% coefficient variation of 22.5% to 24.1%. Of the 2095 male patients tested, 504 (24.1%) were HBsAg positive. Similarly, out of the 871 female subjects, 187 (21.5%) were positive. The differences was not statistically significant ($p=0.13$). An examination of the overall trend of HBsAg seropositivity over the three year study period showed 21.7% in 2001, 24.7% in 2002 and 22.4% in 2003 respectively. The stratification of HBsAg seropositivity by age and by sex are shown in table I and II respectively.

Table III Shows The Trend of Hepatitis B Virus Surface Antigenemia Among Teaching Hospital Patients.

Year	Total Screened	Total Pos	%
2001	406	88	(21.7)
2002	1282	317	(24.7)
2003	1278	286	(22.4)
Total	2,966	691	(23.1)

X²

X²(@1dF and at $P_{0.001} = 13.81$) .Highly significant

Table 1 shows The Distribution of Hepatitis B surface Antigenemia according to Age –Groups.

Age Group (Years)	HBsAg Positive No. (%)	HBsAg Negative No. (%)	Total No.(%)
<10	49(25.3)	145(74.7)	194(100)
11 – 20	93(23.5)	303(76.5)	396(100)
21 – 30	230(24.7)	703(75.3)	933(100)
31 – 40	165(22.8)	559(77.2)	724(100)
41 – 50	87(23.6)	281(76.4)	368(100)
>50	59(17.2)	284(82.8)	343(100)
Not stated	8(100.0)		8(100.0)
Total	691(23.1)	2275(76.9)	2966(100)

χ^2 @1dF and at $P_{0.001} = (13.81)$.Highly significant

Table II shows The Gender Distribution of Hepatitis B surface Antigenemia among Teaching Hospital patients in Kano.

Sex	HBsAg Positive No. (%)	HBsAg Negative No.(%)	Total
Male	504(24.1)	1591(75.9)	2095(100.0)
Female	187(12.5)	684(78.5)	871(100.0)
Total	691(23.3)	2275(76.7)	2966(100.0)

χ^2 at 1dF and $P < 0.05 = 2.3$. Not significant

DISCUSSION

Viral Hepatitis is a major problem in Nigeria and constitute a threat to life of infected patients both young and old. HBV can cause

persistent infection in chronic carriers and progressively cause terminal liver diseases (3&7). Studies have shown that the carrier rate of HBV in Nigeria is between 8 – 22% with an estimated

exposure rate of above 60% (8,9&10). This is consistent with this study, which showed a prevalence rate of 23.1% over a 3-year period. This relatively stable rate may reflect the adequacy of blood transfusion services with respect to screening for HBV infection in blood donors (3).

Although the seroprevalence rate observed in this study is consistent with other studies in Nigeria, it is however higher than 10% found in Pakistan (11&12) and 5% in India (13). But when compared with the rate observed in other African countries, the seroprevalence rate observed in this study is lower than 79% reported in Ethiopia, 56.2% in Kenya and 79.2% in Mozambique (5). Among the various viral Hepatitis, the HBV is more distributed and spreading at the rate which is higher than HIV within the individuals (13). Seroprevalence rate of HBV has been reported in patients with different ailments in Nigeria such as Sickle Cell disease (14), Acute Icteric Hepatitis (15), Diabetes Mellitus (16) and HepatoCellular Carcinoma (17). The prevalence in these various disease conditions are not different from that observed in the general population except for HepatoCellular Carcinoma and Acute Icteric Hepatitis.

There was no significant difference in the prevalence rate of infection in the various age groups except for those in the age of above 50years. This may be due to the small number of patients in this age group (Table 1).

Conversely, the seropositivity in the males were higher than in the females patients (Table 1). This is also consistent with other authors⁵ who reported a higher carriage rate of 77% in males than 50% in females in South Africa. The trend of infection within the study period is statistically significant ($P < 0.001$).

In Africa, transmission of HBV is usually horizontal in childhood. The prevalence of HBV

among pregnant women is said to be much lower than in Chinese women and so vertical transmission is less important.

Some risk factors identified among the study subjects include previous blood transfusion, traditional surgery, scarification, occupational exposure and exposure to infected sex partners. Social status appears to have no effect in carriage of HBV in this study population.

It is necessary to reappraise measures of prevention of HBV infection in order to reduce the trend of infection. Emphasis should be placed on immunization of those at risk, avoidance of sharp objects and contaminated infection, vigorous screening of all blood and blood products to be transfused, practice of safer sex, good personal hygiene and health workers must use the Universal Precaution for protection.

REFERENCES

1. Ayoola, E. A. Viral hepatitis in Africa in the 90s: facing realities. *Viral hepatitis and liver diseases*. 1994; 381 – 384.
2. Kire, C. F. Hepatitis B Infection in Sub Saharan African. The African Regional study group. *Vaccine*. 1990, 8:107 – 112.
3. Faso'a, F. A. Odaibo G. N, Aken'Ova Y.A and O'aleye, O. D. Hepatitis B and C Viral markers in patients with Sickle Cell disease in Ibadan, Nigeria. *Afri. J. Med. Sci.* 2003, 32: 293 – 295.
4. Bayer, M. R, Blumberg, BS and Weiner B. Particles associated with Australia's antigen in the sera of patients with Leukaemia, Down Syndrome and Hepatitis.
5. Malu, A.O. Viral Hepatitis B: Time for action in Nigeria. *Med,-Link. J.* 2003; 4(4): 10 – 12.

6. Takalmawa, H.U., Emokpae, M. A., Abubakar A. G, and Kwaru A. H. Prevalence of Hepatitis B, surface Antigen and Human Immunodeficiency Virus antibodies among blood donors in Aminu Kano Teaching Hospital, Kano - Nigeria, 1996 – 2001, *Hamdaw Med.* 2004; XLVII, 2: 54 – 57.
7. Aken'Ova, Y. A, Olasode, B. J, and Ogunbiyi, J. O, Thomas, J. O Hepatobilliary changes in Mgenawis with Sickle Cell anaemia, *Annals of Trop. Med. and Parasitology* 1993; 87; (6): 603 – 606.
8. Olaleye, O. O, Ekweozor C. C and Meyer. C. Hepatitis B surface antigen in patients attending the sexually transmitted disease clinic in Ibadan, Nigeria, *Afri. J. Med. Sci.* 1996; 25; 117 – 121.
9. Harry T. O, Bajani M D and Moses A. E Hepatitis B virus infection among blood donors and pregnant women in Maiduguri, Nigeria *East Afr. Med. J.* 1994; 71 (9): 596 – 597.
10. Bojuwoye B. J. The burden of Viral Hepatitis in Africa. *West Afr. J. Med.* 1997; 16(4): 198 – 203.
11. Sanjrani, M. A Hepatitis B: Causes Preventions and treatment – *Health Magazine, Daily Awani Awaz, Karachi* 1997;5.
12. Editorial, control of Hepatitis B; need for Universal Immunization. *Quart. Med. channel, Karachi* 1996:5.
13. Dharejo, A. M. Liver eating Virus – In *Health Magazine, Daily Awani Awaz Karachi* 1998:5.
14. Haliru, N. K, Ajayi, O. I. Risk factors and seroprevalence of hepatitis C antibody in blood donors in Nigeria. *East Afr. Med. J.* 2000; 77(8): 410 – 412.
15. Ola, S. O, Otegbayo, J. A Odaibo G. W, Olaleye O.O, Olubuyide, O. L, Senu Hepatitis C virus and Hepatitis B surface antigenaeruis in Nigerian patients with acute Icteric Hepatitis *West. Afr. J. Med.* 2002; 21(3): 215 – 217
16. Onyekwere C. A, Anòmneze E. E, Wali S.S, Prevalence of serological markers of chronic Hepatitis B Virus infection in diabetics in the Lagos University Teaching Hospital, Lagos. *Nig. Postgrad. Med.J.* 2002; 9(3):129 – 133.
17. Olubuyide, I. O., Aliyu B., Olaleye, O. A, Ola, S. O., Olawuyi, F., Malabu, U.H., Odemuyiwa, S. O., Odaibo, G. N., Cook, G. C. Hepatitis B and C Virus and Hepatocellular Carcuridma. *Trans. R. Soc, Trop. Med. Hyg.* 1997; 91(4): 491 – 492.